Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Overview of attention for article published in Journal for Immunotherapy of Cancer, December 2018

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Good Attention Score compared to outputs of the same age and source (73rd percentile)

So far, Altmetric has seen 17 X posts from 11 X users, with an upper bound of 30,941 followers.

RT @sitcancer: #JITC Research: Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy https://t.co/DsX8s41Pst https://t.co/…

#JITC Research: Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy https://t.co/DsX8s41Pst https://t.co/vc1P50nvcL

RT @sitcancer: #JITC Research: Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy https://t.co/DsX8s41Pst https://t.co/…

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 13 additional X posts.